DMAC
DiaMedica Therapeutics Inc
7.60$
-2.8%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -21.0% | +742.1% | -3.8% | +917.7% | -50.6% | +210.3% | +62.1% | -24.5% | +57.5% | -14.4% | +32.4% | |
| – | -21.8% | +790.6% | -19.4% | +1,102.9% | -50.8% | +216.0% | +62.7% | -25.5% | +58.6% | -16.9% | +35.9% | |
| – | -18.7% | +947.9% | -22.1% | +1,143.4% | -76.9% | +90.8% | -36.5% | +0.4% | -3.9% | -33.4% | +417.3% | |
| – | -18.7% | +947.9% | -22.1% | +1,143.4% | -53.2% | +249.2% | +64.0% | -25.7% | +57.9% | -16.5% | +35.7% | |
| – | +14.4% | +440.5% | +53.9% | +707.5% | +27.4% | -58.7% | -61.8% | -36.9% | +350.0% | -36.0% | +9.3% | |
| – | – | -100.0% | – | – | – | -88.6% | +1,030.0% | – | – | – | – | |
| – | -7.5% | +35.3% | +90.8% | +159.5% | +126.0% | -65.9% | +51.4% | +400.0% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -19.8% | -56.8% | +60.0% | +31.0% | +9.3% | +44.9% | -26.6% | +68.2% | +20.8% | +81.3% | -6.5% | |
| – | -41.2% | -41.1% | +60.0% | +29.2% | +1.7% | +53.9% | -24.9% | +42.3% | +28.5% | +93.5% | -4.8% | |
| – | – | -23.3% | -100.0% | – | +1,100.0% | +8.3% | -24.6% | +40.8% | +20.3% | +24.1% | +8.7% | |
| – | -29.8% | -62.9% | +105.2% | -5.8% | -62.3% | +503.8% | -53.7% | +44.2% | +26.2% | +1.5% | +56.9% | |
| – | – | -100.0% | – | – | – | – | – | – | – | – | – | |
| – | – | – | -35.9% | +2,030.8% | -55.3% | +241.5% | +69.2% | -27.7% | +60.4% | -20.2% | +37.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +16.7% | +30.7% | +25.3% | +30.5% | +54.8% | +30.8% | +32.5% | +27.3% | +23.2% | +24.1% | +16.3% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.